These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 21642381

  • 21. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G.
    Clin Cancer Res; 2011 Oct 15; 17(20):6531-41. PubMed ID: 21890455
    [Abstract] [Full Text] [Related]

  • 22. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.
    Cancer Res; 2003 Aug 15; 63(16):5073-83. PubMed ID: 12941837
    [Abstract] [Full Text] [Related]

  • 23. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
    Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ.
    Mol Cancer Ther; 2009 May 15; 8(5):1095-105. PubMed ID: 19366899
    [Abstract] [Full Text] [Related]

  • 24. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR.
    Clin Cancer Res; 2005 Apr 15; 11(8):3065-74. PubMed ID: 15837762
    [Abstract] [Full Text] [Related]

  • 25. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.
    Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M.
    Clin Cancer Res; 2012 Jun 15; 18(12):3407-13. PubMed ID: 22553344
    [Abstract] [Full Text] [Related]

  • 26. Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells.
    Zamri N, Masuda N, Oura F, Yajima Y, Nakada H, Fujita-Yamaguchi Y.
    Biosci Trends; 2012 Dec 15; 6(6):303-12. PubMed ID: 23337790
    [Abstract] [Full Text] [Related]

  • 27. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):67-75. PubMed ID: 20486173
    [Abstract] [Full Text] [Related]

  • 28. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
    Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, Oh DY, Im SA, Bang YJ, Yi EC, Kim TY.
    PLoS One; 2012 Jul 15; 7(3):e33322. PubMed ID: 22438913
    [Abstract] [Full Text] [Related]

  • 29. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.
    Gualberto A, Karp DD.
    Clin Lung Cancer; 2009 Jul 15; 10(4):273-80. PubMed ID: 19632947
    [Abstract] [Full Text] [Related]

  • 30. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 31. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
    Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, Han SK, Shim YS, Coffee K, Dikov MM, Carbone DP.
    Cancer Gene Ther; 2003 Jan 15; 10(1):57-63. PubMed ID: 12489029
    [Abstract] [Full Text] [Related]

  • 32. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
    Zhang T, Shen H, Dong W, Qu X, Liu Q, Du J.
    Sci Rep; 2014 Oct 31; 4():6855. PubMed ID: 25358597
    [Abstract] [Full Text] [Related]

  • 33. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP, Gleave ME, Cox ME.
    Prostate; 2010 Feb 01; 70(2):206-18. PubMed ID: 19790231
    [Abstract] [Full Text] [Related]

  • 34. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM.
    Cancer Res; 2010 Sep 15; 70(18):7221-31. PubMed ID: 20807811
    [Abstract] [Full Text] [Related]

  • 35. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 36. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
    Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG, Trudel S.
    Clin Cancer Res; 2011 Jul 15; 17(14):4693-704. PubMed ID: 21632854
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 40. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.
    Clin Cancer Res; 2009 Sep 01; 15(17):5445-56. PubMed ID: 19706799
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.